Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A
Choose another version >>

Archived Clinical Summary

Depression in Children and Adolescents: Screening

Originally published on: January 9, 2014

This recommendation statement is currently archived and inactive. It should be used for historical purposes only. Click here for copyright and source information .

Disclaimer:Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Archived: Clinical Summary of U.S. Preventive Services Task Force Recommendation

This document is a summary of the 2009 recommendation of the U.S. Preventive Services Task Force (USPSTF) on screening and treatment for major depressive disorder in children and adolescents. This summary is intended for use by primary care clinicians.


 

Population Adolescents (12-18 years) Children (7-11 years)
Recommendation Screen (when systems for diagnosis, treatment, and follow-up are in place) No Recommendation
Grade: B Grade: I
(Insufficient Evidence)
Risk Assessment
Risk factors for major depressive disorder (MDD) include parental depression, having comorbid mental health or chronic medical conditions, and having experienced a major negative life event.
Screening Tests
The following screening tests have been shown to do well in teens in primary care settings:
  • Patient Health Questionnaire for Adolescents (PHQ-A).
  • Beck Depression Inventory-Primary Care Version (BDI-PC).
Screening instruments perform less well in younger children.
Treatments
Among pharmacotherapies fluoxetine, a selective serotonin reuptake inhibitor (SSRI), has been found efficacious. However, because of risk of suicidality, SSRIs should be considered only if clinical monitoring is possible. Various modes of psychotherapy, and pharmacotherapy combined with psychotherapy, have been found efficacious.
Evidence on the balance of benefits and harms of treatment of younger children is insufficient for a recommendation.

For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, please go to: http://www.uspreventiveservicestaskforce.org.

Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

 

Copyright and Source Information

This document is in the public domain within the United States.

Requests for linking or to incorporate content in electronic resources should be sent via the USPSTF contact form.

Current as of: March 2009

Internet Citation: Clinical Summary: Depression in Children and Adolescents: Screening. U.S. Preventive Services Task Force. February 2014.
https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/depression-in-children-and-adolescents-screening

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857